Illumina Inc
NASDAQ:ILMN

Watchlist Manager
Illumina Inc Logo
Illumina Inc
NASDAQ:ILMN
Watchlist
Price: 135.21 USD 0.16% Market Closed
Market Cap: 21.4B USD
Have any thoughts about
Illumina Inc?
Write Note

Illumina Inc
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Illumina Inc
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
Illumina Inc
NASDAQ:ILMN
Retained Earnings
-$1.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Retained Earnings
$51.4B
CAGR 3-Years
15%
CAGR 5-Years
19%
CAGR 10-Years
18%
Danaher Corp
NYSE:DHR
Retained Earnings
$43.3B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
8%
Mettler-Toledo International Inc
NYSE:MTD
Retained Earnings
$8.1B
CAGR 3-Years
13%
CAGR 5-Years
14%
CAGR 10-Years
14%
Agilent Technologies Inc
NYSE:A
Retained Earnings
$750m
CAGR 3-Years
29%
CAGR 5-Years
N/A
CAGR 10-Years
-19%
IQVIA Holdings Inc
NYSE:IQV
Retained Earnings
$5.6B
CAGR 3-Years
43%
CAGR 5-Years
42%
CAGR 10-Years
N/A
No Stocks Found

Illumina Inc
Glance View

Market Cap
21.5B USD
Industry
Life Sciences Tools & Services
Economic Moat
None

In the world of genomics, Illumina Inc. stands as a pioneer, reshaping the landscape of genetic sequencing with a precision that borders on artistry. This San Diego-based company, founded in 1998, has become an industry cornerstone by unlocking the potential of the human genome through its advanced sequencing technologies. Illumina's success is anchored in its innovative creation of next-generation sequencing platforms, which enable researchers to analyze DNA at a scale and speed previously thought impossible. By providing the tools that sequence, analyze, and interpret vast amounts of genetic data, Illumina plays a crucial role in driving discoveries in personalized medicine, agriculture, and countless other fields. At the heart of Illumina's business model lies its suite of sequencing instruments and consumables, which form the backbone of its revenue generation. Their sequencing machines, ranging from behemoth instruments capable of cracking the human genome to compact devices used for focused applications, operate much like a razor-and-blade model. Once customers invest in Illumina's platforms, they continue to purchase consumable products, including reagents and advanced software, crucial for each sequencing run. This model not only fosters continuous engagement with their user base but also sustains a steady revenue stream. By expanding its reach into genomic-based clinical applications, Illumina has also started tapping into diagnostic markets, promising to transform the future of healthcare while ensuring sustained growth for the company.

ILMN Intrinsic Value
144.78 USD
Undervaluation 7%
Intrinsic Value
Price

See Also

What is Illumina Inc's Retained Earnings?
Retained Earnings
-1.4B USD

Based on the financial report for Sep 29, 2024, Illumina Inc's Retained Earnings amounts to -1.4B USD.

Back to Top